Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations

Patrick C Lee; Andrew Hendifar; Arsen Osipov; May Cho; Daneng Li; Jun Gong

doi:10.3390/cancers13071706

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations

Cancers (Basel). 2021 Apr 3;13(7):1706. doi: 10.3390/cancers13071706.

Authors

Patrick C Lee¹, Andrew Hendifar¹, Arsen Osipov¹, May Cho^{2

3}, Daneng Li⁴, Jun Gong¹

Affiliations

¹ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
² Department of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.
³ UCI Health Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.
⁴ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Abstract

Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarcinoma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.

Keywords: TAS-120; cholangiocarcinoma; debio 1347; derazantinib; erdafitinib; fibroblast growth factor receptor (FGFR); futibatinib; infigratinib; pemigatinib.

Publication types

Review